UHT Stock Analysis: Universal Health Realty | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 605m USD | 12M Return: 16.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 8.68M
EPS Trend: 28.8%
Rev. Trend: 71.9%
Warnings
Tailwinds
No distinct edge detected
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Universal Health Realty Income Trust (NYSE: UHT) is a Maryland-incorporated real estate investment trust (REIT) that invests in healthcare and human service-related facilities, including acute care hospitals, behavioral healthcare facilities, rehabilitation hospitals, sub-acute care facilities, surgery centers, childcare centers, and medical office buildings. Founded in 1986 and headquartered in King of Prussia, Pennsylvania, the Trust holds seventy-seven investments across twenty-one states and trades as a small-cap stock following its 1987 IPO.
As a healthcare REIT, UHT generates revenue primarily through leasing arrangements with operators of medical and human service facilities, a model that typically involves long-term, triple-net leases and requires the Trust to comply with REIT-specific tax regulations that mandate distribution of most taxable income to shareholders.
- Rising interest rates pressure healthcare REIT valuations and dividend yields
- Tenant concentration with Universal Health Services impacts rental income stability
- Medicare and Medicaid reimbursement cuts threaten hospital operator lease payments
| Net Income: 17.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.09 > 0.02 and ΔFCF/TA 0.61 > 1.0 |
| NWC/Revenue: -238.0% < 20% (prev -243.6%; Δ 5.66% < -1%) |
| CFO/TA 0.09 > 3% & CFO 49.4m > Net Income 17.9m |
| Net Debt (393.5m) to EBITDA (64.6m): 6.09 < 3 |
| Current Ratio: 0.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (13.9m) vs 12m ago 0.17% < -2% |
| Gross Margin: 90.49% > 18% (prev 94.40%; Δ -3.92% > 0.5%) |
| Asset Turnover: 26.14% > 50% (prev 17.16%; Δ 8.98% > 0%) |
| Interest Coverage Ratio: 1.25 > 6 (EBIT TTM 35.7m / Interest Expense TTM 28.4m) |
| A: -0.63 (Total Current Assets 20.2m - Total Current Liabilities 374.0m) / Total Assets 563.8m |
| B: -0.23 (Retained Earnings -126.9m / Total Assets 563.8m) |
| C: 0.06 (EBIT TTM 35.7m / Avg Total Assets 568.6m) |
| D: 0.36 (Book Value of Equity 147.8m / Total Liabilities 416.0m) |
| Altman-Z'' = -4.06 = D |
| DSRI: 0.10 (Receivables 13.2m/113.3m, Revenue 148.7m/98.4m) |
| GMI: 1.04 (GM 94.40% / 90.49%) |
| AQI: 1.22 (AQ_t 0.94 / AQ_t-1 0.77) |
| SGI: 1.51 (Revenue 148.7m / 98.4m) |
| TATA: -0.06 (NI 17.9m - CFO 49.4m) / TA 563.8m) |
| Beneish M = -3.23 (Cap -4..+1) = AA |
As of July 18, 2026, the stock is trading at USD 43.84 with a total of 79,834 shares traded. Over the past week, the price has changed by +1.81%, over one month by +15.34%, over three months by +4.02% and over the past year by +16.09%.
Current recommended Stop Loss: 41.30 (which is 5.8% or 2.1 ATR below the current price).
Universal Health Realty has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy UHT.
- StrongBuy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 42 | -4.2% |
P/E Trailing = 34.0703
P/E Forward = 38.7597
P/S = 5.9931
P/B = 4.1025
P/EG = 0.6292
Revenue TTM = 148.7m USD
EBIT TTM = 35.7m USD
EBITDA TTM = 64.6m USD
Long Term Debt = 18.3m USD (from longTermDebt, last quarter)
Short Term Debt = 359.5m USD (from shortLongTermDebt, last quarter)
Debt = 400.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 11.4m
Net Debt = 393.5m USD (calculated: Debt 400.6m - CCE 7.06m)
Enterprise Value = 998.6m USD (605.1m + Debt 400.6m - CCE 7.06m)
Interest Coverage Ratio = 1.25 (Ebit TTM 35.7m / Interest Expense TTM 28.4m)
EV/FCF = 20.20x (Enterprise Value 998.6m / FCF TTM 49.4m)
FCF Yield = 4.95% (FCF TTM 49.4m / Enterprise Value 998.6m)
FCF Margin = 33.25% (FCF TTM 49.4m / Revenue TTM 148.7m)
Net Margin = 12.01% (Net Income TTM 17.9m / Revenue TTM 148.7m)
Gross Margin = 90.49% ((Revenue TTM 148.7m - Cost of Revenue TTM 14.1m) / Revenue TTM)
Gross Margin QoQ = 70.59% (prev 94.43%)
Tobins Q-Ratio = 1.77 (Enterprise Value 998.6m / Total Assets 563.8m)
Interest Expense / Debt = 7.10% (Interest Expense 28.4m / Debt 400.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 28.2m (EBIT 35.7m * (1 - 21.00%))
Current Ratio = 0.05 (Total Current Assets 20.2m / Total Current Liabilities 374.0m)
Debt / Equity = 2.71 (Debt 400.6m / totalStockholderEquity, last quarter 147.8m)
Debt / EBITDA = 6.09 (Net Debt 393.5m / EBITDA 64.6m)
Debt / FCF = 7.96 (Net Debt 393.5m / FCF TTM 49.4m)
Total Stockholder Equity = 156.0m (last 4 quarters mean from totalStockholderEquity)
RoA = 3.14% (Net Income 17.9m / Total Assets 563.8m)
RoE = 11.44% (Net Income TTM 17.9m / Total Stockholder Equity 156.0m)
RoCE = 20.46% (EBIT 35.7m / Capital Employed (Equity 156.0m + L.T.Debt 18.3m))
RoIC = 15.31% (NOPAT 28.2m / Invested Capital 184.0m)
WACC = 6.23% (E(605.1m)/V(1.01b) * Re(6.64%) + D(400.6m)/V(1.01b) * Rd(7.10%) * (1-Tc(0.21)))
Discount Rate = 6.64% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 96.81 | Cagr: 0.17%
[DCF] Terminal Value 76.16% ; FCFF base≈48.4m ; Y1≈50.9m ; Y5≈59.0m
[DCF] Fair Price = 37.20 (EV 909.6m - Net Debt 393.5m = Equity 516.1m / Shares 13.9m; r=8.35% [WACC [floored]]; 5y FCF grow 5.66% → 2.50% )
EPS Correlation: 28.80 | EPS CAGR: 1.93% | SUE: N/A | # QB: 0
Revenue Correlation: 71.89 | Revenue CAGR: 14.13% | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS next Quarter (2026-09-30): EPS=0.00 | Chg30d=N/A | Revisions=N/A | Analysts=0
EPS current Year (2026-12-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+0.0% | GrowthRev=-0.1%
EPS next Year (2027-12-31): EPS=0.00 | Chg30d=N/A | Revisions=N/A | GrowthEPS=+0.0% | GrowthRev=+5.2%